|

NST-628 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Nested Therapeutics, Inc1

Indications

  • MAPK Pathway Gene Mutation1
  • RAF Gene Mutation1
  • MEK Mutation1
  • Ras (Kras or Nras) Gene Mutation1
  • Melanoma1

San Francisco, California1 trial

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.